|
|
|
|
|
|
|
|
|
|
|
|
Discussion of Human Gene Transfer Protocol #0401-624: |
|
|
|
A Phase I Trial of Conditionally Replication-Competent Adenovirus (Delta-24-RGD) for Recurrent Malignant Gliomas |
|
|
|
Frederick F. Lang, Jr., M.D., University of Texas M.D. Anderson Cancer Center, Houston, TX |
|
|
|
Presentation Webcast
Slides
Review Webcast
|
|
|
|
|
RAC Recommendations |
|
|
|
Webcast
|
|
|
|
|
|
Discussion of Human Gene Transfer Protocol #0401-625: |
|
|
|
A Phase I Study of a Tropism-Modified Conditionally Replicative Adenoviral Vector (Ad5-?24RGD) for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients |
|
|
|
Ronald D. Alvarez, M.D., University of Alabama, Birmingham |
|
|
|
Webcast
Slides
|
|
|
|
|
RAC Recommendations |
|
|
|
Webcast
|
|
|
|
|
|
Discussion of Human Gene Transfer Protocol #0311-614: |
|
|
|
First Time in Human Safety Study of Streptococcus mutans Lactic Acid-Deficient Effector Strain (A2JM) Administered in Conjunction with Twice-Daily Dose of D-Alanine Mouthwash in Healthy Adult Male Subjects for Replacement Therapy as an Aid in the Protection Against Dental Caries |
|
|
|
Constance E. Stone, D.M.D., University of Florida, Gainesville, FL |
|
|
|
Webcast
Slides part 1
Slides part 2
|
|
|
|
|
RAC Recommendations |
|
|
|
Webcast
|
|
|
|
|
Update on the RAC Gene Transfer Clinical Trial Design Working Group |
|
|
|
David DeMets, Ph.D., NIH RAC |
|
|
|
Webcast
|
|
|
|
|
ADJOURN |
|
|
|
Top of Page |
|